Sabby Management, LLC
Sabby Management, LLC is an exempt reporting adviser that reports managing 1 hedge fund on Form ADV. Its private funds, of all types, hold $52.8 million in gross assets. Over a longer period they returned an estimated +7.0% from Q2 2026 to Q2 2026, compared with +14.8% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- —Form ADV Item 5.F
- Gross assets of private funds
- $52.8 millionAll private fund types, Form ADV
- Hedge funds managed
- 12 private funds in total
- Employees
- —Form ADV Item 5.A
- Registration
- Exempt reporting adviserCRD 162659
- Latest Form ADV
- 07/08/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +7.0% | +14.8% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 14 share positions ($6,690,050) reported by Sabby Management, LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 13, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Toyo Co LTD31.35%
- PN Smart Energy LTD11.02%
- YXT Com Group Hldg LTD9.66%
- Zevra Therapeutics Inc9.49%
- Cervomed Inc8.86%
- Aptevo Therapeutics Inc6.33%
- Ishares TR4.15%
- Paranovus Entertnmnt Tech LT3.90%
- Senestech Inc3.17%
- China Pharma Hldgs Inc3.03%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Toyo Co LTD | $2,097,461 | 31.35% | 482,175 | -4.30% |
| PN Smart Energy LTD | $737,060 | 11.02% | 269,000 | New |
| YXT Com Group Hldg LTD | $646,552 | 9.66% | 286,085 | New |
| Zevra Therapeutics Inc | $634,615 | 9.49% | 57,850 | New |
| Cervomed Inc | $593,044 | 8.86% | 199,678 | -19.77% |
| Aptevo Therapeutics Inc | $423,499 | 6.33% | 232,692 | New |
| Ishares TR | $277,890 | 4.15% | 1,000 | New |
| Paranovus Entertnmnt Tech LT | $260,624 | 3.90% | 64,671 | -14.27% |
| Senestech Inc | $211,896 | 3.17% | 313,132 | +10.45% |
| China Pharma Hldgs Inc | $202,593 | 3.03% | 308,360 | New |
| Can Fite Biofarma LTD | $187,455 | 2.80% | 85,207 | New |
| Briacell Therapeutics Corp | $158,183 | 2.36% | 136,365 | -28.37% |
| Sidus Space Inc | $155,488 | 2.32% | 85,905 | +98.04% |
| Revelation Biosciences Inc | $103,690 | 1.55% | 126,915 | -39.73% |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 7 new positions, 9 sold out, 2 increased, 5 reduced and 0 unchanged.
Number of positions (a count, not dollars)
- New positions7
- Increased2
- Unchanged0
- Reduced5
- Sold out9
New positions
| Stock | Value | Shares |
|---|---|---|
| PN Smart Energy LTD | $737,060 | 269,000 |
| YXT Com Group Hldg LTD | $646,552 | 286,085 |
| Zevra Therapeutics Inc | $634,615 | 57,850 |
| Aptevo Therapeutics Inc | $423,499 | 232,692 |
| Ishares TR | $277,890 | 1,000 |
| China Pharma Hldgs Inc | $202,593 | 308,360 |
| Can Fite Biofarma LTD | $187,455 | 85,207 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| State STR SPDR S&P 500 ETF T | $4,107,235 | 5,500 |
| Farmmi Inc | $840,307 | 3,515,929 |
| Tempest Therapeutics Inc | $567,527 | 511,286 |
| Bioaffinity Technologies Inc | $296,905 | 365,647 |
| Smart Powerr Corp | $263,214 | 127,774 |
| Briacell Therapeutics Corp | $261,536 | 80,721 |
| Inmed Pharmaceuticals Inc | $69,704 | 44,970 |
| Nuwellis Inc | $49,935 | 16,372 |
| Briacell Therapeutics Corp | $11,464 | 120,802 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Sidus Space Inc | +42,528 | +98.04% | $155,488 | 85,905 |
| Senestech Inc | +29,620 | +10.45% | $211,896 | 313,132 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Cervomed Inc | -49,202 | -19.77% | $593,044 | 199,678 |
| Toyo Co LTD | -21,671 | -4.30% | $2,097,461 | 482,175 |
| Revelation Biosciences Inc | -83,667 | -39.73% | $103,690 | 126,915 |
| Briacell Therapeutics Corp | -54,018 | -28.37% | $158,183 | 136,365 |
| Paranovus Entertnmnt Tech LT | -10,769 | -14.27% | $260,624 | 64,671 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Oragenics Inc | 13G | 9.9% | 412,654 | Jan 21, 2026 | SEC.gov ↗ |
| Tempest Therapeutics, Inc. | 13G | 9.9% | 492,223 | Jan 21, 2026 | SEC.gov ↗ |
| Jiuzi Holdings, Inc. | 13G amendment | 9.9% | 206,273 | Jan 21, 2026 | SEC.gov ↗ |
| Globavend Holdings Ltd | 13G | 9.9% | 211,464 | Jan 21, 2026 | SEC.gov ↗ |
| Foxo Technologies Inc. | 13G | 9.9% | 249,316,528 | Jan 21, 2026 | SEC.gov ↗ |
| Revelation Biosciences, Inc. | 13G | 9.6% | 605,702 | Jan 20, 2026 | SEC.gov ↗ |
| Nuwellis, Inc. | 13G | 5.4% | 89,685 | Jan 20, 2026 | SEC.gov ↗ |
| Lyra Therapeutics, Inc. | 13G | 9.9% | 175,158 | Jan 20, 2026 | SEC.gov ↗ |
| InMed Pharmaceuticals Inc. | 13G | 9.9% | 280,138 | Jan 20, 2026 | SEC.gov ↗ |
| Biodexa Pharmaceuticals Plc | 13G | 9.9% | 217,600 | Jan 20, 2026 | SEC.gov ↗ |
| Big Tree Cloud Holdings Ltd | 13G | 6.6% | 5,769,988 | Jan 20, 2026 | SEC.gov ↗ |
| Universe Pharmaceuticals INC | 13G amendment | 4.9% | 28,111 | Jan 7, 2026 | SEC.gov ↗ |
| Empery Digital Inc. | 13G amendment | 1.3% | 479,428 | Jan 7, 2026 | SEC.gov ↗ |
| BNB Plus Corp. | 13G amendment | 4.9% | 217,840 | Jan 7, 2026 | SEC.gov ↗ |
| Transcode Therapeutics, Inc. | 13G amendment | 4.9% | 41,601 | Jan 7, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Jan 7, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 16 companies. Source: U.S. Securities and Exchange Commission, EDGAR.
Private funds reported on Form ADV (2)
As reported in the adviser's Form ADV filed Mar 27, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures